Halozyme Therapeutics

Halozyme Therapeutics

Yahoo Finance • 3 hours ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was grante... Full story

Yahoo Finance • 12 hours ago

Halozyme Therapeutics Inc (HALO) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...

This article first appeared on GuruFocus. Total Revenue: $493 million, up 39% year over year from $354.3 million. Royalty Revenue: Record $341 million, up 44% year over year. DARZALEX Royalty Revenue: $153.5 million, up 20% year over year... Full story

Yahoo Finance • 18 hours ago

Halozyme falls 6% as raised guidance fails to impress investors

Investing.com -- Halozyme Therapeutics Inc (NASDAQ:HALO) reported third-quarter results that exceeded Wall Street expectations, but shares tumbled 6% in after-hours trading Thursday as the company's raised full-year guidance met elevated i... Full story

Yahoo Finance • 10 days ago

Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth Momentum

Renaissance Investment Management, an investment management company, released its Q3 2026 investor letter for "Large Cap Growth Strategy." The letter can be downloaded here. Stocks showed modest gains in Q3, with the S&P 500 up 2.3%. Energ... Full story

Yahoo Finance • 14 days ago

How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots Continue Reading... Full story

Yahoo Finance • 14 days ago

BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.

Oncology-focused biotech firm BeOne Medicines explores buy zone, boosted by strong demand and stellar earnings growth. Continue Reading... Full story

Yahoo Finance • 14 days ago

How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots Continue Reading... Full story

Yahoo Finance • 15 days ago

BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.

Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth. Continue Reading... Full story

Yahoo Finance • 21 days ago

5 Stocks to Buy Using the Relative Price Strength Strategy

U.S. equities continue to show resilience despite a volatile backdrop. The S&P 500 has faced pressure from weakness in AI-linked technology stocks, but rotation into other sectors suggests the market's underlying strength is broader than a... Full story

Yahoo Finance • 23 days ago

Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight

Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch. Continue Reading... Full story

Yahoo Finance • 29 days ago

Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?

Halozyme's argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock's pa... Full story

Yahoo Finance • 30 days ago

Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?

In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries following a patent dispute. This setback affe... Full story

Yahoo Finance • 30 days ago

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 30 days ago

Halozyme stock rises after winning injunction against Merck

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets. Before you buy NVIDIA: our AI model's stock... Full story

Yahoo Finance • last month

1 Cash-Producing Stock to Target This Week and 2 We Question

1 Cash-Producing Stock to Target This Week and 2 We Question Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to... Full story

Yahoo Finance • 2 months ago

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of precision oncology. According to BioPharma Di... Full story

Yahoo Finance • 2 months ago

Halozyme prices $1.3B convertible senior notes offering due 2033

* Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]) on Thursday announced the pricing of $1.3B aggregate principal amount of 1.50% convertible senior notes due 2033. * The offering size was increased from the previou... Full story

Yahoo Finance • 2 months ago

4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears

The U.S. economy is entering a more challenging environment as renewed Middle East tensions push oil prices above $100 a barrel, adding to inflationary pressures. Annual CPI inflation accelerated to 3.4% in August, well above the Federal R... Full story

Yahoo Finance • 2 months ago

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:... Full story

Yahoo Finance • 2 months ago

Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?

Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) offers broad healthcare exposure at a fraction of the cost, while First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides an aggressive, concentrated focus on biotechnology i... Full story